NEWS 
& MEDIA

MEDIA
CONTACT

Welcome to the Takeda Oncology Newsroom. This section is dedicated to providing the most up-to-date information about our company, our people and our science.

If you are a reporter, please contact:
Phone: 617-444-1400
Email: TakedaOncologyNews@takeda.com

For other Takeda news releases, please visit the Takeda.com Newsroom. 

GO TO TAKEDA NEWSROOM

NEWS
RELEASES

4/6/2020

European Commission Approves Takeda‚Äôs ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ NSCLC

READ MORE  
3/31/2020

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) in Combination with CHP (Cyclophosphamide, Doxorubicin and Prednisone) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

READ MORE  
3/10/2020

Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial

READ MORE